Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 3/20 | 0.43 |
| ▸ | CA6 | P23280 | 3/20 | 0.43 |
| ▸ | CA5A | P35218 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.32 |
| ▸ | CASP2 | P42575 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052175 | 1.00 | NFKB1 (0.46) | NFKB1DNM1CA12CA2CA4 | |
| SCHEMBL11423017 | 0.96 | NFKB1 (0.43) | NFKB1DNM1CA12CA2CA4 | |
| SCHEMBL11436103 | 0.96 | NFKB1 (0.43) | NFKB1DNM1CA12CA2CA4 | |
| SCHEMBL434923 | 0.93 | — | — | |
| SCHEMBL434924 | 0.93 | — | — | |
| SCHEMBL4449966 | 0.89 | — | — | |
| SCHEMBL11523771 | 0.89 | DNM1 (0.53) | NFKB1DNM1CA12CA2CA4 | |
| SCHEMBL19805247 | 0.89 | — | — | |
| SCHEMBL10816439 | 0.89 | NFKB1 (0.38) | NFKB1DNM1CA12CA2CA4 | |
| SCHEMBL10816441 | 0.89 | NFKB1 (0.38) | NFKB1DNM1CA12CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092160-A2 | BIFUNCTIONAL PROTEASES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022036229-A2 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20090286628-A1 | GOLF BALL HAVING A HARD OUTER SKIN | ACUSHNET COMPANY | 2009-11-19 | — | — | US | disclosed |
| US-20090283932-A1 | Dual Cured Castable System for Use in Golf Balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2009-11-19 | — | — | US | disclosed |
| US-20090286626-A1 | Dual Cured Castable Polyurea System for Use in Golf Balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2009-11-19 | — | — | US | disclosed |
| US-20080221020-A1 | Dendrimers as Molecular Translocators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | disclosed |
| EP-1545462-A4 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | UNIV CALIFORNIA (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060216265-A1 | Dendrimers as molecular translocators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-09-28 | — | — | US | disclosed |
| EP-1545462-A2 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | The Regents of the University of California (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004009666-A2 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009665-A2 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-01-29 | — | — | WO | disclosed |
| US-4197260-A | FROM DIALDEHYDES | SNIA VISCOSA, SOCIETA NAZIONALE INDUSTRIA APPLICAZIONI VISCOSA S.P.A. (IT) | 1980-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | NFKB1 4291/4885DNM1 574/4885CA12 399/4885 |
| US-20060216265-A1 | Dendrimers as molecular translocators | SLC29A1, SLC29A2, TSPO | NFKB1 2702/4885DNM1 357/4885CA12 4480/4885 |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | NFKB1 4291/4885DNM1 574/4885CA12 399/4885 |
| US-20080221020-A1 | Dendrimers as Molecular Translocators | SLC29A1, SLC29A2, TSPO | NFKB1 2702/4885DNM1 357/4885CA12 4480/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | NFKB1 4291/4885DNM1 574/4885CA12 399/4885 |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | ENTPD1, ENTPD2, ENTPD5 | NFKB1 1873/4885DNM1 1265/4885CA12 2200/4885 |
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | FCGR3B, FCGR1A, FCGR2A | NFKB1 2071/4885DNM1 37/4885CA12 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.